Loading...
XNYSLLY
Market cap728bUSD
Dec 20, Last price  
767.76USD
1D
1.35%
1Q
-16.68%
Jan 2017
943.86%
Name

Eli Lilly and Co

Chart & Performance

D1W1MN
XNYS:LLY chart
P/E
139.08
P/S
21.36
EPS
5.52
Div Yield, %
0.56%
Shrs. gr., 5y
-2.66%
Rev. gr., 5y
9.69%
Revenues
34.12b
+19.56%
13,857,900,00014,645,300,00015,691,000,00018,633,500,00020,378,000,00021,836,000,00023,076,000,00024,286,500,00022,603,400,00023,113,100,00019,615,600,00019,958,700,00021,222,100,00022,871,300,00021,493,300,00022,319,500,00024,539,800,00028,318,400,00028,541,400,00034,124,100,000
Net income
5.24b
-16.08%
1,810,100,0001,979,600,0002,662,700,0002,953,000,000-2,071,900,0004,328,800,0005,069,500,0004,347,700,0004,088,600,0004,684,800,0002,390,500,0002,408,400,0002,737,600,000-204,100,0003,232,000,0004,637,900,0006,193,700,0005,581,700,0006,244,800,0005,240,400,000
CFO
4.24b
-40.15%
2,869,500,0001,913,600,0003,975,900,0005,154,500,0007,295,600,0004,335,500,0006,856,800,0007,234,500,0005,304,800,0005,735,000,0004,367,100,0002,772,800,0004,851,000,0005,615,600,0005,524,500,0004,836,600,0006,499,600,0007,260,700,0007,084,400,0004,240,100,000
Dividend
Feb 14, 20251.5 USD/sh
Earnings
Feb 04, 2025

Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
URL
https://www.lilly.com/
IPO date
Jul 09, 1970
Employees
39,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
34,124,100
19.56%
28,541,400
0.79%
28,318,400
15.40%
Cost of revenue
23,292,500
21,261,000
21,970,300
Unusual Expense (Income)
NOPBT
10,831,600
7,280,400
6,348,100
NOPBT Margin
31.74%
25.51%
22.42%
Operating Taxes
1,314,200
561,600
573,800
Tax Rate
12.13%
7.71%
9.04%
NOPAT
9,517,400
6,718,800
5,774,300
Net income
5,240,400
-16.08%
6,244,800
11.88%
5,581,700
-9.88%
Dividends
(4,069,300)
(3,535,800)
(3,086,800)
Dividend yield
0.77%
1.07%
1.23%
Proceeds from repurchase of equity
(750,000)
(1,500,000)
(1,250,000)
BB yield
0.14%
0.45%
0.50%
Debt
Debt current
6,904,500
1,501,100
1,538,300
Long-term debt
19,428,200
14,737,500
15,346,400
Deferred revenue
5,874,100
Other long-term liabilities
7,528,600
6,751,400
1,644,300
Net debt
20,352,800
11,125,000
9,763,500
Cash flow
Cash from operating activities
4,240,100
7,084,400
7,260,700
CAPEX
(7,392,100)
(2,484,000)
(1,873,200)
Cash from investing activities
(7,152,700)
(3,261,600)
(2,762,300)
Cash from financing activities
3,495,600
(5,406,700)
(4,131,300)
FCF
7,135,900
6,403,700
5,749,600
Balance
Cash
2,927,700
2,211,800
3,908,600
Long term investments
3,052,200
2,901,800
3,212,600
Excess cash
4,273,695
3,686,530
5,705,280
Stockholders' equity
6,670,700
6,917,700
5,387,300
Invested Capital
35,494,705
29,603,770
28,043,700
ROIC
29.24%
23.31%
20.09%
ROCE
27.24%
21.81%
18.05%
EV
Common stock shares outstanding
903,284
904,619
911,681
Price
582.92
59.34%
365.84
32.45%
276.22
63.60%
Market cap
526,542,309
59.10%
330,945,815
31.42%
251,824,526
63.45%
EV
546,986,909
342,196,415
261,763,626
EBITDA
12,358,900
8,802,900
7,895,700
EV/EBITDA
44.26
38.87
33.15
Interest
312,300
331,600
339,800
Interest/NOPBT
2.88%
4.55%
5.35%